Skip to main content
Premium Trial:

Request an Annual Quote

BGI to Demo RNA-seq's Ability to Predict Patient Outcomes as Part of FDA-Led SEQC Project

Premium

BGI said last week that it is conducting RNA-seq studies in 500 neuroblastoma samples to show the technique's ability to predict patient outcomes as part of the US Food and Drug Administration's Sequencing Quality Control Project.

SEQC is the third phase of the MicroArray Quality Control project and aims to assess the technical performance of next-generation sequencing platforms for RNA and DNA analyses.

BGI said that it will perform the library construction, sequencing, and bioinformatics analysis for the 500 neuroblastoma samples. The results will be compared to microarray data.

The University Children's Hospital of Cologne is collaborating with BGI on the project. "While we have built predictive models for neuroblastoma patients with microarray data, some of those still need to be improved," Matthias Fischer, a researcher at the university, said in a statement.

Compared to microarrays, RNA-seq data could be utilized to "better understand human transcriptomics and identify functional genetic variants associated with disease and drug risks," he added.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.